• Content
  • Search
  • Navigation
  • Sitemap
  • About us
    • About us
    • Who we are
    • Our model
    • The Syncona platform
    • Data driven investment process
    • Our purpose, culture and values
    • Our history
  • Our people
    • Our people
    • Board of directors
  • Portfolio
    • Portfolio
    • Cell therapy
      • Overview
      • Autolus
      • Achilles Therapeutics
      • Quell Therapeutics
      • Resolution Therapeutics
      • Neogene Therapeutics
      • Clade Therapeutics
    • Gene therapy
      • Overview
      • Freeline Therapeutics
      • SwanBio Therapeutics
      • Purespring Therapeutics
    • Biologics
      • Overview
      • Anaveon
    • Small molecule
      • Overview
      • OMass Therapeutics
    • Previous investments
      • Overview
      • Gyroscope Therapeutics
      • Blue Earth
      • Nightstar
      • 14MG
      • Azeria Therapeutics
  • Sustainability
    • Sustainability
    • Message from Chief Executive, SIML
    • Our social impact
    • Responsible investor and partner
      • Overview
      • Responsible investment process
      • A responsible partner
    • Inspiring and empowering our people
    • Responsible and ethical business
      • Overview
      • Environment
    • Aligning with UN SDGs
    • Syncona’s approach to charity
      • Overview
      • The Syncona Foundation
    • Sustainability policies
  • News and Insights
  • Investors
    • Investors
    • Investment case
    • KPIs
    • Results and presentations
    • RNS and inside information
    • Share price centre
    • Governance
      • Overview
      • Our Committees
      • How we communicate with our stakeholders
    • Regulatory publications
    • Financial calendar
    • Analysts and advisers
    • Shareholder information
      • Overview
      • Shareholder documents
    • FAQs
  • Contact

News

Show
  • Sustainability
  • Financial
  • Operating News
news from
  • all companies
  • Syncona
  • all Cell therapy companies
  • Autolus
  • Achilles Therapeutics
  • Quell Therapeutics
  • Resolution Therapeutics
  • Neogene Therapeutics
  • Clade Therapeutics
  • all Gene therapy companies
  • Freeline Therapeutics
  • SwanBio Therapeutics
  • Purespring Therapeutics
  • all Biologics companies
  • Anaveon
  • all Small molecule companies
  • OMass Therapeutics
18.05.22

SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions

  • Operating News
  • Gene therapy
  • SwanBio Therapeutics
17.05.22

Additional Preclinical Data Supports Clinical Advancement of First AAV-Based Gene Therapy for Adrenomyeloneuropathy

  • Operating News
  • Gene therapy
  • SwanBio Therapeutics
10.05.22

Freeline Reports First Quarter 2022 Financial Results and Business Highlights

  • Operating News
  • Gene therapy
  • Freeline Therapeutics
02.05.22

Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy

  • Operating News
  • Gene therapy
  • Freeline Therapeutics
19.04.22

Freeline Appoints Paul Schneider as Chief Financial Officer

  • Operating News
  • Gene therapy
  • Freeline Therapeutics
05.04.22

Updated Preclinical Data Support Potential of First AAV-Based Gene Therapy as a Treatment for Adrenomyeloneuropathy

  • Operating News
  • Gene therapy
  • SwanBio Therapeutics
Load more

Sign-up for company news alerts

Get the latest RNS, company news, share price information and results from Syncona

  • RNS alerts
  • Company alerts

Syncona Investment Management Limited
2nd Floor
8 Bloomsbury Street
London
WC1B 3SR
contact@synconaltd.com

  • About us
  • Our people
  • Portfolio
  • Sustainability
  • News and Insights
  • Investors
  • Contact
  • Copyright © Syncona 2022
  • Accessibility
  • Privacy & cookies
  • Employee privacy notice
  • Third party privacy notice
  • Regulatory publications
  • Modern Slavery Statement

Syncona Limited is registered in Guernsey no. 55514, registered office Arnold House, PO Box 273, St Julian’s Avenue, St Peter Port, Guernsey GY1 3RD.
Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

Designed & built by SampsonMay
  • About us
    • About us
    • Who we are
    • Our model
    • The Syncona platform
    • Data driven investment process
    • Our purpose, culture and values
    • Our history
  • Our people
    • Our people
    • Board of directors
  • Portfolio
    • Portfolio
    • Cell therapy
      • Overview
      • Autolus
      • Achilles Therapeutics
      • Quell Therapeutics
      • Resolution Therapeutics
      • Neogene Therapeutics
      • Clade Therapeutics
    • Gene therapy
      • Overview
      • Freeline Therapeutics
      • SwanBio Therapeutics
      • Purespring Therapeutics
    • Biologics
      • Overview
      • Anaveon
    • Small molecule
      • Overview
      • OMass Therapeutics
    • Previous investments
      • Overview
      • Gyroscope Therapeutics
      • Blue Earth
      • Nightstar
      • 14MG
      • Azeria Therapeutics
  • Sustainability
    • Sustainability
    • Message from Chief Executive, SIML
    • Our social impact
    • Responsible investor and partner
      • Overview
      • Responsible investment process
      • A responsible partner
    • Inspiring and empowering our people
    • Responsible and ethical business
      • Overview
      • Environment
    • Aligning with UN SDGs
    • Syncona’s approach to charity
      • Overview
      • The Syncona Foundation
    • Sustainability policies
  • News and Insights
  • Investors
    • Investors
    • Investment case
    • KPIs
    • Results and presentations
    • RNS and inside information
    • Share price centre
    • Governance
      • Overview
      • Our Committees
      • How we communicate with our stakeholders
    • Regulatory publications
    • Financial calendar
    • Analysts and advisers
    • Shareholder information
      • Overview
      • Shareholder documents
    • FAQs
  • Contact
GBX 177.00
Change: -2.80 (-1.56%)

Search